Clinical trialPhase 2Terminated
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Phase II Study of Panobinostat (LBH589) Given in Combination With Bortezomib (Velcade) in Patients With Pancreatic Cancer Progressing on Gemcitabine Therapy Alone or Gemcitabine in Combination
- Outcome
- Stopped earlyFunding not available (Business decision)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- September 2010
- Expected end
- February 2011
- Enrollment
- 7 participants
- Sites
- 1
- Primary outcomes
- Progression-Free Survival
- Sponsor
- Other
- Results posted
- 2011-08-26
- Last update
- 28 December 2017
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Cancer results from multiple mutations which cause cells to grow uncontrolled. It therefore may be necessary to inhibit several oncogenic targets to affect cancer cell growth. Studies have shown that panobinostat (LH589) causes a wide range of effect on endothelial cells that lead to inhibition of tumor angiogenesis (a fundamental step in the transition of tumors from a dormant state to a malignant one). Bortezomib triggers cell death in pancreatic cancer cells but the mechanism is not well defined but has been determined to be cytostatic. Combining these two drugs may work together in the treatment of pancreatic cancer.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Progression-Free Survival [Up to 1 Year]. Median, Months (95% Confidence Interval). Pancreatic Cancer Patients (n=7): 2.1 (1.7 to 2.3).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants by Tumor Response [Up to 1 Year]. Number, Participants. Progressive Disease: Pancreatic Cancer Patients (n=7): 5. No data available: Pancreatic Cancer Patients (n=7): 2. Objective Response: Pancreatic Cancer Patients (n=7): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Duration of Response [Up to 1 Year]. Number, Weeks. Pancreatic Cancer Patients (n=7): 0.